The use of subcutaneous glycopyrrolate in the management of sialorrhoea and facilitating the use of non-invasive ventilation in amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis

Volumn 12, Issue 6, 2011, Pages 464-465

  Cooper Knock, Johnathan ^a,c   Ahmedzai, Sam H ^b   Shaw, Pamela ^a  

^a SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

amyotrophic lateral sclerosis; Glycopyrrolate; non invasive ventilation; sialorrhoea

Indexed keywords

AMITRIPTYLINE; ATROPINE; BOTULINUM TOXIN B; GLYCOPYRRONIUM BROMIDE; PROPANTHELINE BROMIDE; SCOPOLAMINE BROMIDE;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ARTIFICIAL VENTILATION; BLURRED VISION; CASE REPORT; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; HYPERSALIVATION; MULTIPLE CYCLE TREATMENT; NON INVASIVE PROCEDURE; NON INVASIVE VENTILATION; PRIORITY JOURNAL; RESPIRATORY FAILURE; TREATMENT OUTCOME;

AMYOTROPHIC LATERAL SCLEROSIS; FEMALE; GLYCOPYRROLATE; HUMANS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; SIALORRHEA; TREATMENT OUTCOME; VENTILATION;

EID: 80055032901     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.3109/17482968.2011.584195     Document Type: Article

References (10)

1. Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice Parameter update. The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioural impairment (an evidence-based review). Neurology. 2009; 73:1227-33.
2. Hadjikoutis S, Wiles CM. Respiratory complications related to bulbar dysfunction in motor neuron disease. Acta Neurologica Scandinavica. 2001;103:207-13. (Pubitemid 32304256)
3. Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomized controlled trial. The Lancet Neurology. 2006;5:140-7. (Pubitemid 43109171)
4. Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN, et al. Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence based review with good practice points. EALSC Working Group. Amyotroph Lateral Scler. 2007;8:195-213. (Pubitemid 47190223)
5. Mirakhur RK, Dundee JW. Comparison of the effects of atropine and glycopyrrolate on various end-organs. J R Soc Med. 1980;73:727-30. (Pubitemid 11233505)
6. Arbouw MEL, Movig KLL, Koopmann M, Poels PJE, Guchelaar H-J, Egberts TCG, et al. Glycopyrrolate for sialorrhoea in Parkinson ' s disease. Neurology. 2010; 74:1203-7.
7. Fuder H, Meincke M. Glycopyrronium bromide blocks differentially responses mediated by muscarinic receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 1993;347:591-5. (Pubitemid 23181412)
8. Strutt R, Fardell B, Chye R. Nebulized glycopyrrolate for drooling in a motor neuron patient. Journal of Pain and Symptom Management. 2002;23:2-3. (Pubitemid 34093871)
9. Jackson CE, Gronseth G, Rosenfeld J, Barohn RJ, Dubinsky R, Simpson CB, et al. Randomized double-blind study of botulinum toxin type B for sialorrhoea in ALS patients. Muscle & Nerve. 2009;39:137-43.
10. Dogu O, Apaydin D, Sevim S, Talas DU, Aral M. Ultrasoundguided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson ' s disease. Clinical Neurology and Neurosurgery. 2004;106:93-6. (Pubitemid 38299270)